Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Asil, SERKAN; Kaya, Baris; CANPOLAT, UĞUR; YORGUN, HİKMET; Sahiner, Levent; ÇÖTELİ, CEM; Arat, ANIL; AYTEMİR, KUDRET

doi:10.1002/ccd.27442

Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Copy For Citation

Asil S., Kaya B., CANPOLAT U., YORGUN H., Sahiner L., ÇÖTELİ C., ...More

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, vol.92, no.3, pp.557-565, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 92 Issue: 3
Publication Date: 2018
Doi Number: 10.1002/ccd.27442
Journal Name: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.557-565
Hacettepe University Affiliated: Yes

Abstract

Aims: Percutaneous septal reduction therapy by either alcohol or nonalcohol agents is an alternative approach to surgery in drug-refractory symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Nonalcohol agents have some advantages and disadvantages over alcohol during the procedure. Nowadays, a novel non-alcohol agent, named as Ethylene-vinyl alcohol (EVOH) copolymer (Onyx (R) and Squid (R)), is used during septal ablation. Thus, in this study, we aimed to evaluate both acute and long-term efficacy and safety profile of EVOH during septal ablation in HOCM.